RecruitingPhase 2NCT04787289

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer - a Pragmatic Trial

Sponsor

British Columbia Cancer Agency

Enrollment

244 participants

Start Date

Sep 10, 2021

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer Platinum Resistant Ovarian Cancer

Summary

A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy. The study will be offered to ovarian cancer patients whose disease is platinum chemotherapy resistant . Higher doses of anti-cancer based drugs are not always better than lower doses and can cause more side effects without improvement of cancer. These patients will be randomly assigned either 7.5 mg/kg or 15mg/kg of bevacizumab combined with chemotherapy . Comparing these two doses will determine if the lower dose-level is non-inferior, and could lead to practice changes.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is comparing two different doses of bevacizumab (a drug that cuts off blood supply to tumors) when combined with chemotherapy, in women with advanced or recurrent ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. **You may be eligible if...** - You have a confirmed diagnosis of advanced or recurrent epithelial ovarian, peritoneal, or fallopian tube cancer - Your cancer has come back or progressed within 6 months of completing platinum-based chemotherapy - There is no curative treatment currently available for your cancer - Your cancer can be measured on scans **You may NOT be eligible if...** - Your cancer responded well to platinum-based chemotherapy (i.e., it is platinum-sensitive) - You have other serious health conditions that may affect your ability to tolerate treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBevacizumab

Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)

Locations(2)

Abbotsford Centre, BC Cancer Agency

Abbotsford British Columbia, British Columbia, Canada

BC Cancer - Vancouver

Vancouver, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04787289

Related Trials

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT0702362782 locations

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779162 locations

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467167 locations

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

NCT073711041 location